Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Nucl Med Commun ; 45(2): 155-160, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-38010319

ABSTRACT

Radionuclide ventriculography or Multi Gated Acquisition (MUGA) employing [ 99m Tc]Technetium red blood cell (RBC) labeling is considered the gold standard for cardiotoxicity assessments in cancer patients undergoing chemotherapy. This in-vivo RBC labeling technique involves the reduction of [ 99m Tc]Technetium by the stannous chloride present in freeze-dried reagent kits, with the pyrophosphate kit (PYP) being the most employed for this purpose. The literature, however, describes diethylenetriaminepentaacetic acid (DTPA) as an alternative to PYP, although a lack of comparative data from MUGA images between both reagents is noted. A retrospective cross-sectional observational study was conducted at the Brazilian National Cancer Institute Nuclear Medicine Service concerning 80 randomized MUGA images, 20 obtained employing DTPA between 2020 and 2023 and 60 obtained employing PYP between 2017 and 2020, applying the mean count per pixel (ct/pixel) and heart background (C/F) ratios as quality image indicators. Although the heart ct/pixel ratio was statistically lower in the DTPA images compared with PYP ( P  = 0.02), the C/F ratio was statistically similar when comparing both radiopharmaceuticals ( P  = 0.697). A semi-quantitative analysis of MUGA images obtained with DTPA and PYP indicates similar image quality, supporting the use of DTPA as an alternative to PYP without compromising diagnostic interpretations.


Subject(s)
Radiopharmaceuticals , Technetium , Humans , Cross-Sectional Studies , Retrospective Studies , Radionuclide Ventriculography , Pentetic Acid , Erythrocytes
2.
Radiat Prot Dosimetry ; 199(11): 1195-1201, 2023 Jul 05.
Article in English | MEDLINE | ID: mdl-37247636

ABSTRACT

COVID-2019 has resulted in an emerging respiratory infection that has spread as a pandemic since January 2020. Nuclear Medicine Services and its workers experienced a dramatic change in their clinical routine. They were required to adjust protocols for this new health condition. Regarding radioiodine therapy (RIT), initial orientations were to postpone treatments. In Brazil, National Nuclear Energy Commission prepared guidelines. It authorized RIT to employ activities over 1850 MBq in an outpatient setting on an exceptional basis. This study reports the RIT experience of a Brazilian hospital during the COVID-19 pandemic, intending to evaluate the applicability of outpatient treatment employing over 1850 MBq of I-131 on a large scale. During referred period, 106 patients at our service had an indication for RIT, of which 58 agreed to participate in the research and provided informed consent. Majority of patients did not meet the minimum requirements for outpatient treatment using doses > 1850 MBq.


Subject(s)
COVID-19 , Humans , COVID-19/radiotherapy , Iodine Radioisotopes/therapeutic use , Brazil/epidemiology , Pandemics , Hospitals
3.
Curr Radiopharm ; 9(1): 54-63, 2016.
Article in English | MEDLINE | ID: mdl-25771373

ABSTRACT

The optimization of DOTA-NHS-ester conjugation to Rituximab using different Ab:DOTA molar ratios (1:10, 1:20, 1:50 and 1:100) was studied. High radiochemical yield, in vitro stability and immunoreactive fraction were obtained for the Rituximab conjugated at 1:50 molar ratio, resulting in the incorporation of an average number of 4.9 ± 1.1 DOTA per Rituximab molecule. Labeling with 177Lu was performed in high specific activity with great in vitro stability. Biodistribution in healthy and xenographed mice showed tumor uptake and high in vivo stability as evidenced by low uptake in bone. The properties of 177Lu-DOTA-Rituximab prepared from DOTA-NHS-ester suggest the potential for the application of the 177Lu-labeled antibody in preliminary clinical studies.


Subject(s)
Lutetium/administration & dosage , Lymphoma, Non-Hodgkin/radiotherapy , Radiopharmaceuticals/administration & dosage , Rituximab/administration & dosage , Animals , Drug Stability , Humans , Lutetium/chemistry , Lutetium/pharmacokinetics , Mice , Mice, SCID , Radiopharmaceuticals/chemistry , Radiopharmaceuticals/pharmacokinetics , Rituximab/chemistry , Rituximab/pharmacokinetics , Succinimides/chemistry , Tissue Distribution , Xenograft Model Antitumor Assays
4.
Appl Radiat Isot ; 96: 91-101, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25479439

ABSTRACT

We evaluated and compared a new bombesin analog [Tyr-Gly5, Nle(14)]-BBN(6-14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC-3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTA-peptide to PC-3 cells was observed. Both peptides could target PC-3 and LNCaP tumors in vivo and both tumor types could be visualized by microSPECT/CT.


Subject(s)
Bombesin/analogs & derivatives , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/metabolism , Heterocyclic Compounds, 1-Ring , Pentetic Acid/analogs & derivatives , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/metabolism , Radiopharmaceuticals , Receptors, Bombesin/metabolism , Animals , Bombesin/chemistry , Cell Line, Tumor , Drug Stability , Female , Heterografts , Humans , In Vitro Techniques , Indium Radioisotopes , Male , Mice, SCID , Neoplasm Transplantation , Radionuclide Imaging , Radiopharmaceuticals/chemistry , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...